Ranbaxy Laboratories, one of the leading pharma players, witnessed a rise in share price on Monday after it announced the launch of Infimab, the first Remicade (Infliximab) biosimilar in India. The product was launched at the Indian Rheumatology Association Conference (IRACON) in Chandigarh, in the presence of over a thousand rheumatologists and doctors from around the country.

Shares of the company are trading at Rs 633.70, up Rs 21.3, or 3.48% at the Bombay Stock Exchange (BSE) on Monday at 11:54 a.m.

The scrip has touched an intra-day high of Rs 634.90 and low of Rs 620. The total volume of shares traded at the BSE is 91,039.